Direct renin inhibition: An analysis of possible benefits

Current Hypertension Reports

Volumn 10, Issue 4, 2008, Pages 313-318

  Dockery, Brian K ^b   Bisognano, John D ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALISKIREN; ALISKIREN PLUS HYDROCHLOROTHIAZIDE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALKIREN; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; LOSARTAN; PLACEBO; RAMIPRIL; RENIN; RENIN INHIBITOR; UNCLASSIFIED DRUG; VALSARTAN; ZANKIREN; AMIDE; CELL SURFACE RECEPTOR; FUMARIC ACID DERIVATIVE; PRORENIN RECEPTOR;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; GENETIC MANIPULATION; HEART INJURY; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY INJURY; MONOTHERAPY; MORBIDITY; MORTALITY; NONHUMAN; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; STEADY STATE; UNITED STATES; UNSPECIFIED SIDE EFFECT; ANIMAL; BLOOD; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; PHYSIOLOGY;

AMIDES; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; DRUG EVALUATION, PRECLINICAL; FUMARATES; HUMANS; HYPERTENSION; RECEPTORS, CELL SURFACE; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 52449128804     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-008-0058-2     Document Type: Review

References (50)

1. Skeggs LT, Kahn JR, Lentz KE, Shumway NP: Preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med 1957, 106:439-453.
2. Neal B, MacMahon S, Chapman N: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials: Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000, 356:1955-1964.
3. Zannad F, Alla F, Dousset B, et al.: RALES Investigators: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 2000, 102:2700-2706. [Erratum, Circulation 2001, 103:476.]
4. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329: 1456-1462.
5. Ruggenenti P, Perna A, Gherardi G, et al.: Renoprotective properties of ACE-inhibition in nondiabetic nephropathies with nonnephrotic proteinuria. Lancet 1999, 354:359-364.
6. Rongen GA, Lenders JWM, Smits P, Thien T. Clinical pharmacokinetics and efficacy of renin inhibitors. Clin Pharmacokinet 1995, 29:6-14.
7. Sielecki AR, Hayakawa K, Fujinaga M, et al.: Structure of recombinant human renin, a target for cardiovascular-active drugs, at 2.5 A resolution. Science 1989, 243:1346-1351.
8. Rahuel V, Rasetti J, Maibaum H, et al.: Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol 2000, 7:493-504.
9. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001, 345:1689-1697.
10. Nguyen G, Delarue F, Berrou J, et al.: Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int 1996, 50:1897-1903.
11. Ferrario CM: The renin angiotensin system: importance in physiology and pathology. J Cardiovasc Pharmacol 1990, 15(Suppl 3):S1-S5.
12. Dzau VJ: Tissue angiotensin and pathobiology of vascular disease. A unifying hypothesis. Hypertension 2001, 37:1047-1052.
13. Richard V, Hurel-Merle S, Scalbert E, et al.: Functional evidence for a role of vascular chymase in the production of angiotensin II in isolated human arteries. Circulation 2001, 104:750-752.
14. Linz W, Wiemer G, Gohlke P, et al.: Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995, 47:25-49.
15. Bing J: Rapid marked increase in plasma renin in rats treated with inhibitors of the renin system. Effects of 1-sar-8-ala-angiotensin-II and of a synthetic converting enzyme inhibitor (nonapeptide, SQ 20.881) on normal and adrenalectomized rats. Acta Pathol Mocrobiol Scand[Al 1973, 81:376-378.
16. Juillerate L, Nussberger J, Menard J, et al.: Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension [1990, 16:564-572.
17. Borghi C, Boschi S, Ambrosioni E, et al.: Evidence of a partial escape of the renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 1993, 33:40-45.
18. 18 Roig E, Perez-Villa F, Morales M, et al.: Clinical Implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000, 21:53-57.
19. Alderman MH, Ooi WL, Cohen H, et al.: Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens 1997, 10:1-8.
20. Luetscher JA, Kraemer FB, Wilson DM, et al.: Increased plasma renin activity in diabetes mellitus: a marker of microvascular complications. N Engl J Med 1985, 312:1412-1417.
21. Packer M, Poole-Witson PA, Armstrong PW, et al.: Comparative effects of low and high doses of the angiotensin-converting-enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure: ATLAS Study Group. Circulation 1999, 23:2312-2318.
22. Doulton TW, He FJ, MacGregor GA: Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005, 45:880-886.
23. Azizi M, Menard J: Combined blockade of the renin-angiotensin system with angiotensin-converting-enzyme inhibitors and angiotcnsin II type I receptor antagonists. Circulation 2004, 109:2492-2499.
24. Nakamura Y, Yoshiyama M, Omura T, et al.: Beneficial effects of combination of ACE inhibitor and angiotensin II type 1 receptor blocker on cardiac remodeling in rat myocardial infarction. Cardiovasc Res 2003, 57:48-54.
25. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001:345:1667-1675.
26. McMurray JJV, Ostergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-vetricular systolic function taking angiotensin-converting-enzyme. Lancet 2003, 363:767-771.
27. Ferrari P, Marti HP, Pfister M, Fey FJ: Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens 2002, 20:125-130.
28. Nguyen G, Delarue F, Burcklè C, et al.: Pivotal role of the renin/ prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002, 109:14117-1427.
29. Huang Y, Wongamornthan S, Kasting J, et al.: Renin increases mesangial cell TGF-β1 and matrix proteins through receptor-mediated, Ang II-independent mechanisms. Kidney Int 2006, 69:105-113.
30. Rongen GA, Lenders JWM, Smits P, Thien T. Clinical pharmacokinetics and efficacy or renin inhibitors. Clin Pharmacokinet 1995, 29:6-14.
31. Frampton JE, Curran MP: Atiskiren: a review of its use in the management of hypertension. Drugs 2007, 67:1767-1792.
32. Nussberger J, Wuerzner G, Jensen C, Brunner HR: Renin inhibitor aliskiren (SPP100) comparison with enalapril. Hypertension 2002, 39:el-e8.
33. Dahlöf B, Anderson DR, Arora V, et al.: Aliskiren, a direct renin inhibitor, provides antihypertensive efficacy and excellent tolerability independent of age or gender in patients with hypertension [abstract]. J Clin Hypertens 2007,9(Suppl A):A1S7.
34. Villamil A, Chrysant SG, Calhoun D, et al.: Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007,25:217-226.
35. Jordan J, Engeli S, Boye SW, et al.: Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007, 49:1047-1055.
36. Uresin Y, Taylor A, Kilo C, et al.: Aliskiren, a novel renin inhibitor, has greater BP lowering than ramipril and additional BP lowering when combined with ramiprit in patients with diabetes and hypertension [abstract]. J Hypertens 2006, 24(Suppl 4):82.
37. Oparil S, Yarrows SA, Patel S, et al.: Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized double-blind trial. Lancet 2007,370:221-229.
38. Gradman AH, Schmieder RE, Lins RL, et al.: Aliskiren, a novel, orally effective renin inhibitor, provides antihypertensive efficacy and placebo-like tolerability similar to an AT1-receptor blocker in hypertensive patients. Circulation 2005, 111:1012-1018.
39. Stanton A, Jensen C, Nussberger J, et al.: Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003, 42 b:1137-1143.
40. Oh BH, Mitchell J, Herron JR, et al.: Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-h blood pressure control in patients with hypertension. Am Coll Cardiol 2007, 49:1157-1163.
41. Keefe DL, Andersen K,Weinberger MH, et al.: Blood pressure towering effects persist following the last dose of long-term therapy with aliskiren, an oral direct renin inhibi- tor [abstract]. J Am Coll Cardiol 2007,49(Suppl A):372.
42. Pool J, Gradman A, Kolloch R, et al.: Aliskiren, a novel renin inhibitor, provides long-term suppression of the rennin system, when used alone or in combination with hydrochlorothiazide in the treatment of hypertension [abstract]. Eur Heart J 2006,27(Suppl): 119.
43. Feldman DL, Persohn E, Schutz H, et al.: Renal localization of the renin inhibitor aliskiren [abstract]. J Clin Hypertens 2006, 8(Suppl A):A80.
44. Gradman AH, Kad R: Renin inhibition in hypertension. Am Coll Cardiol 2008, 51:519-528.
45. Fisher ND, Hollenberg N: Renal vascular responses to renin inhibition with zankiren in men. Clin Pharmacol Ther 1995, 57:342-348.
46. Cordero PL, Fisher NDL, Moore TJ, et al.: Renal and endocrine r esponse to a renin inhibitor, enalkiren, in normal humans. Hypertension 1991, 17:510-516.
47. We Pilz B, Shagdarsuren E, Wellner M, et al.: Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005, 46:569-576.
48. McMurray J: Hemodynamic, neurohormonal, renal, and ambulatory effects of a new oral renin inhibitor in stable heart failure. Presented at the European Society of Cardiology Congress 2007. Vienna, Austria; September 2, 2007.
49. Sealey JE, Laragh JH: Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens 2007, 20:587-597.
50. Ménard J, Azizi M: The difficult conception, birth, and delivery of a renin inhibitor: controversies around aliskiren. J Hypertens 2007, 25:1775-1782.